悦康药业双链siRNA新药获批临床近日,悦康药业集团股份有限公司子公司北京悦康科创医药科技股份有限公司、杭州天龙药业有限公司获得国家药品监督管理局(NMPA)核准签发的关于YKYY013注射液用于治疗慢性乙型肝炎病毒感染的《药物临床试验批准通知书》,悦康药业将开展本品I期临床试验。YKYY013注射液是悦康科创和杭州天龙自主研发的一款偶联N-乙酰半乳糖胺(N-acetylgalactosamine...
Source Link悦康药业双链siRNA新药获批临床近日,悦康药业集团股份有限公司子公司北京悦康科创医药科技股份有限公司、杭州天龙药业有限公司获得国家药品监督管理局(NMPA)核准签发的关于YKYY013注射液用于治疗慢性乙型肝炎病毒感染的《药物临床试验批准通知书》,悦康药业将开展本品I期临床试验。YKYY013注射液是悦康科创和杭州天龙自主研发的一款偶联N-乙酰半乳糖胺(N-acetylgalactosamine...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.